Atara Biotherapeutics, Inc. (ATRA) EVP Sells $21,429.44 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 1,604 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $13.36, for a total value of $21,429.44. Following the sale, the executive vice president now directly owns 344,134 shares of the company’s stock, valued at $4,597,630.24. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Christopher Haqq also recently made the following trade(s):

  • On Monday, October 16th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $14.35, for a total value of $86,100.00.
  • On Friday, September 15th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $15.30, for a total value of $91,800.00.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) opened at $14.60 on Monday. Atara Biotherapeutics, Inc. has a one year low of $11.80 and a one year high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). equities analysts forecast that Atara Biotherapeutics, Inc. will post -4 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Atara Biotherapeutics, Inc. (ATRA) EVP Sells $21,429.44 in Stock” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/11/20/atara-biotherapeutics-inc-atra-evp-sells-21429-44-in-stock.html.

A number of equities research analysts have recently weighed in on ATRA shares. ValuEngine downgraded Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Canaccord Genuity set a $47.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Monday, August 7th. BidaskClub downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price objective on the stock in a research note on Tuesday, August 22nd. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, August 31st. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. Atara Biotherapeutics presently has an average rating of “Hold” and an average price target of $24.40.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP increased its position in Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after buying an additional 610 shares during the period. American International Group Inc. increased its position in Atara Biotherapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the period. Teachers Advisors LLC increased its position in Atara Biotherapeutics by 2.4% in the 2nd quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock worth $660,000 after buying an additional 1,110 shares during the period. The Manufacturers Life Insurance Company increased its position in Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after buying an additional 1,369 shares during the period. Finally, Alps Advisors Inc. increased its position in Atara Biotherapeutics by 5.8% in the 2nd quarter. Alps Advisors Inc. now owns 26,274 shares of the biotechnology company’s stock worth $368,000 after buying an additional 1,445 shares during the period. 82.52% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

What are top analysts saying about Atara Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Atara Biotherapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit